Comparing Semaglutide, Tirzepatide, and Dual-Compound Options Semaglutide targets GLP-1 receptors alone and produced average weight loss of 15% in landmark trials, making it highly effective for most patients
For patients with CKD, treatment plans are tailored to individual needs to maximize effectiveness while minimizing risks
The FDA based its decision on results from the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial
And at the maximum studied dose of 12 mg, average weight loss hit 24.2% at 48 weeks
Key points to follow: Follow the IMP label or trial protocol for the exact storage temperature and BUD do not assume a temperature range or time window If no BUD is stated , treat the preparation as single-use and administer immediately after reconstitution
For Canadian patients particularly, the conversation around medication dependency carries unique weight given our universal healthcare culture that emphasizes prevention and lifestyle